The increased replicative capacity of a late-stage simian immunodeficiency virus mne variant is evident in macrophage- or dendritic cell-T-cell cocultures

Virology
Jason T KimataParul G Patel

Abstract

Human and simian immunodeficiency virus (HIV and SIV) may co-opt antigen capture and presentation functions of antigen presenting cells (APCs) to facilitate infection of CD4+ T-cells. To address whether the replicative capacity of SIV in the host may be associated with the extent of viral replication in response to APC-T-cell interactions, we compared the replicative phenotypes of cloned early and late-stage SIVmne variants of known pathogenicity. Here, we show that the highly pathogenic late variant SIVmne027 replicates more efficiently in both macrophage- and dendritic cell (DC)-T-cell cocultures than the minimally pathogenic early virus SIVmneCl8. Contact between either macrophages or DC and T-cells increases replication of SIVmne027. Our analysis also demonstrates that mutations in pol and nef contribute to the greater replicative capacity of SIVmne027 in DC- or macrophage-T-cell cocultures. Together, these data suggest that variant viruses that evolve to replicate vigorously in response to APC-T-cell interactions may have increased replicative capacity in vivo.

References

Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M I BukrinskyM Stevenson
Jul 7, 1998·The Journal of Experimental Medicine·T W ChunA S Fauci
Jun 8, 1999·The Journal of Experimental Medicine·D UnutmazD R Littman
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·J A Schrager, J W Marsh
Jan 5, 2000·Proceedings of the National Academy of Sciences of the United States of America·J K WangD Trono
Jan 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·Li WuVineet N KewalRamani
Jan 18, 2003·Immunity·Michael D BobardtPhilippe A Gallay
May 6, 2003·Science·David McDonaldThomas J Hope

❮ Previous
Next ❯

Citations

Mar 27, 2009·AIDS Research and Human Retroviruses·Susan M GrahamJulie Overbaugh
Apr 14, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Reetakshi AroraJason T Kimata
Aug 31, 2013·PLoS Pathogens·Fan WuVanessa M Hirsch
Sep 14, 2010·European Journal of Applied Physiology·Jacob A Wegelin, Martin D Hoffman
Dec 16, 2006·The Journal of General Virology·F J U M van der MeerH F Egberink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.